GNLX - Genelux Corp

2.52
0   0%

Share volume: 131,516
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$2.52
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 43%
Dept financing 25%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.79%
1 Month
1.61%
3 Months
-14.86%
6 Months
-65.48%
1 Year
-13.10%
2 Year
-20.50%
Key data
Stock price
$2.52
P/E Ratio 
N/A
DAY RANGE
$2.47 - $2.60
EPS 
-$0.91
52 WEEK RANGE
$2.26 - $8.54
52 WEEK CHANGE
-$13.10
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
44.806 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
-0.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$139,904
AVERAGE 30 VOLUME 
$222,158
Company detail
CEO: Thomas Zindrick
Region: US
Website: www.genelux.com
Employees: 10
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.

Recent news